Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 two-stage study of setmelanotide in obesity due to specific MC4R-pathway genetic defects
MOH_2022-06-09_011844Phase 2Not yet recruiting
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Jun 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Melanocortin-4 receptor deficiency (MC4RD) comparing Setmelanotide continuation with Placebo withdrawal (2 arms). Primary endpoint: Primary objective. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
setmelanotide
03
Conditions
Melanocortin-4 receptor deficiency (MC4RD)
Beyond the preview
Go deeper on MOH_2022-06-09_011844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-06-09_011844.